** Brokerage Leerink Partners starts coverage of contract research organization Medpace's MEDP.O shares with "market perform" rating and PT of $330
** Brokerage believes MEDP's growth has been affected by elevated cancellation rates and a slowdown in new clinical trial starts due to reduced biotech funding post-COVID
** Brokerage says the firm is well aligned with growing disease categories such as oncology, metabolic and cardiovascular, and its full-service outsourcing (FSO) helps smaller biotechs run efficient clinical trials
** FSO involves handling all aspects of a clinical trial that include initiating the study, analysis, monitoring of trial subjects, ensuring safety and interacting with regulatory bodies
** Brokerage says its PT reflects higher growth prospects and profitability compared with its peers such as IQVIA IQV.N and ICLR ICLR.O
** 4 out 10 brokerages rate the stock "buy" or higher, 6 "hold", median PT $350, according to LSEG data
** As of last close, MEDP stock down 21.5% in past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。